Achieved a third consecutive quarter of year-over-year revenue growth, driven by a deliberate strategic pivot toward the high-demand U.S. AI-driven discovery market.

Signed the first one-year enterprise Lens AI platform contract, transitioning the business model from one-off project fees to predictable, monthly recurring revenue.

Differentiated the Lens AI platform by focusing on the 'invariant functional layer' of biology (HIFT) rather than surface sequence similarity, allowing for the detection of IP risks and functional adjacencies competitors miss.

Validated the HIFT approach by identifying a single conserved functional feature across over 2,000 influenza sequences, representing a potential target for a universal immunogen.

Advanced the dengue program by targeting a single conserved epitope present in all four serotypes, aiming to solve the historical 'antibody-dependent enhancement' failure mode of previous vaccines.

Launched the B Cell LAMA platform to solve the 'chain-pairing problem' in multispecific antibody development by utilizing naturally matured llama nanobodies that lack light chains.

Divested European operations to concentrate capital and resources on North American commercial growth and Canadian laboratory capabilities.

Anticipating near-term data readouts for dengue, GLP-1, and influenza programs, with dengue binding confirmation expected within the current week.

Designing structured asset-level financing vehicles with legal and financial advisers to fund clinical advancement while preserving parent company equity.

Rolling out the Lens AI portal to a broader base of approximately 750 active clients to convert existing fee-for-service relationships into SaaS subscriptions.

Advancing a dual-regimen GLP-1 program that links weight-loss biology to a non-overlapping longevity pathway based on pharma collaborator feedback.

Projecting G&A expenses to remain flat or show modest growth, as current infrastructure is deemed sufficient to support scaling operations.

Reported a significant reduction in net loss to $3.9 million compared to $22 million in the prior year, which was impacted by a $21.2 million impairment charge.

Maintained a cash position of $14.2 million to fund ongoing R&D and commercial expansion in the Boston-Cambridge biotech hub.

Published peer-reviewed research in Biomacromolecules demonstrating that function-based selection provides 10 to 25 times greater potency than traditional affinity-based selection.

Initiated IP protection for 'functional adjacency' capabilities, a new competitive moat for identifying molecules with similar effects but low sequence similarity.

Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here.

Management explained the conversion followed a 'proof-of-concept' period where Lens AI solved scientific challenges that previous AI vendors and wet labs failed to address over a decade.

The transition to recurring revenue is being facilitated by a new digital portal giving 750 active clients direct access to proprietary discovery applications.

While no specific timeline for the next contract was given, management emphasized that these clients are already 'onboarded' in their procurement systems, lowering the barrier to conversion.

Management confirmed that financing structures for dengue, GLP-1, and influenza are moving forward independently of one another.

The company's low R&D burn rate—driven by in-house AI and lab capabilities—allows them to reach IND-enabling stages before requiring external asset-level capital.

Ring-fencing these assets is intended to support the higher costs associated with clinical trials while utilizing internal expertise for the preclinical phase.

One stock. Nvidia-level potential. 30M+ investors trust Moby to find it first. Get the pick. Tap here.